KR101647174B1 - 신규 페놀 유도체 - Google Patents

신규 페놀 유도체 Download PDF

Info

Publication number
KR101647174B1
KR101647174B1 KR1020127007939A KR20127007939A KR101647174B1 KR 101647174 B1 KR101647174 B1 KR 101647174B1 KR 1020127007939 A KR1020127007939 A KR 1020127007939A KR 20127007939 A KR20127007939 A KR 20127007939A KR 101647174 B1 KR101647174 B1 KR 101647174B1
Authority
KR
South Korea
Prior art keywords
added
group
benzothiazole
distilled
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127007939A
Other languages
English (en)
Korean (ko)
Other versions
KR20120080183A (ko
Inventor
세이이치 고바시
준이치로 우다
사치호 미야타
츠토무 이노우에
나오키 아시자와
고지 마츠모토
데츠야 다니구치
다카시 이와나가
오사무 나가타
Original Assignee
가부시키가이샤 후지야쿠힝
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101647174(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 가부시키가이샤 후지야쿠힝 filed Critical 가부시키가이샤 후지야쿠힝
Publication of KR20120080183A publication Critical patent/KR20120080183A/ko
Application granted granted Critical
Publication of KR101647174B1 publication Critical patent/KR101647174B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127007939A 2009-09-30 2010-09-29 신규 페놀 유도체 Active KR101647174B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2009-227402 2009-09-30
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体

Publications (2)

Publication Number Publication Date
KR20120080183A KR20120080183A (ko) 2012-07-16
KR101647174B1 true KR101647174B1 (ko) 2016-08-09

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007939A Active KR101647174B1 (ko) 2009-09-30 2010-09-29 신규 페놀 유도체

Country Status (23)

Country Link
US (1) US8367843B2 (enExample)
EP (1) EP2484669B1 (enExample)
JP (1) JP5325065B2 (enExample)
KR (1) KR101647174B1 (enExample)
CN (1) CN102639518B (enExample)
AU (1) AU2010301675B2 (enExample)
BR (1) BR112012007069B1 (enExample)
CA (1) CA2775309C (enExample)
DK (1) DK2484669T3 (enExample)
ES (1) ES2549603T3 (enExample)
HU (1) HUE026007T2 (enExample)
IL (1) IL218519A (enExample)
IN (1) IN2012DN02551A (enExample)
MX (1) MX2012003392A (enExample)
MY (1) MY160394A (enExample)
NZ (1) NZ598582A (enExample)
PH (1) PH12012500643A1 (enExample)
PL (1) PL2484669T3 (enExample)
PT (1) PT2484669E (enExample)
RU (1) RU2536689C2 (enExample)
TW (1) TWI461195B (enExample)
WO (1) WO2011040449A1 (enExample)
ZA (1) ZA201201895B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
JP6719475B2 (ja) * 2015-09-04 2020-07-08 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
LT3348557T (lt) * 2015-09-10 2020-08-10 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd Imidazo[1,2a]piridinai, skirti hiperurikemijos arba podagros gydymui arba prevencijai
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
PT3484862T (pt) 2016-07-18 2021-11-17 Arthrosi Therapeutics Inc Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
CA3055517A1 (en) * 2017-04-28 2018-11-01 Fuji Yakuhin Co., Ltd. Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3890722A4 (en) 2018-12-06 2022-08-24 Arthrosi Therapeutics, Inc. METHODS OF TREATMENT OR PREVENTION OF GOUT OR HYPERURICAEMIA
US12496293B2 (en) * 2019-12-09 2025-12-16 Fuji Yakuhin Co., Ltd. Solid pharmaceutical preparation
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用
CN119930540A (zh) * 2025-01-21 2025-05-06 杭州善礼生物医药科技有限公司 一种多替诺雷的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
WO2005121112A1 (ja) 2004-06-10 2005-12-22 Torii Pharmaceutical Co., Ltd. ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
WO2007086504A1 (ja) * 2006-01-27 2007-08-02 Japan Tobacco Inc. カルボン酸化合物及びその用途
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Also Published As

Publication number Publication date
CN102639518A (zh) 2012-08-15
TWI461195B (zh) 2014-11-21
JP5325065B2 (ja) 2013-10-23
AU2010301675B2 (en) 2013-08-22
TW201121544A (en) 2011-07-01
RU2536689C2 (ru) 2014-12-27
RU2012117786A (ru) 2013-11-10
ES2549603T3 (es) 2015-10-29
PH12012500643A1 (en) 2012-11-12
PL2484669T3 (pl) 2015-12-31
JP2011074017A (ja) 2011-04-14
AU2010301675A1 (en) 2012-04-05
US8367843B2 (en) 2013-02-05
EP2484669A1 (en) 2012-08-08
PT2484669E (pt) 2015-10-30
DK2484669T3 (en) 2015-09-21
WO2011040449A1 (ja) 2011-04-07
EP2484669B1 (en) 2015-07-29
CN102639518B (zh) 2015-03-25
BR112012007069B1 (pt) 2020-03-03
MX2012003392A (es) 2012-04-10
KR20120080183A (ko) 2012-07-16
EP2484669A4 (en) 2013-02-27
MY160394A (en) 2017-03-15
BR112012007069A2 (pt) 2016-04-19
IL218519A (en) 2016-03-31
ZA201201895B (en) 2013-09-25
CA2775309A1 (en) 2011-04-07
IN2012DN02551A (enExample) 2015-08-28
IL218519A0 (en) 2012-07-31
US20120184587A1 (en) 2012-07-19
NZ598582A (en) 2013-04-26
HUE026007T2 (en) 2016-05-30
HK1169650A1 (en) 2013-02-01
CA2775309C (en) 2017-12-12

Similar Documents

Publication Publication Date Title
KR101647174B1 (ko) 신규 페놀 유도체
JP4503232B2 (ja) マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
US20040248950A1 (en) Apo ai expression accelerating agent
US11306102B2 (en) 1,3-di-substituted ketene compound and application thereof
WO2007097403A1 (ja) 消化管潰瘍治療又は予防薬
JP2008519083A (ja) アミノキナゾリン化合物
CA2998034A1 (en) A group of compounds used for the treatment or prevention of hyperuricemia or gout
JP4894517B2 (ja) ２−フェニルピリジン誘導体
WO2016108282A1 (ja) Ｕｒａｔ１阻害剤
US7612108B2 (en) 2-phenylthiophene derivative
KR101739362B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
JPH0499770A (ja) ロダニン誘導体
JP2003267870A (ja) 肺高血圧症の予防又は治療剤
JP3836521B2 (ja) ２，４−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
KR20170033321A (ko) 아졸벤젠 유도체의 결정
KR20170033320A (ko) 아조르벤젠 유도체 및 그 결정
CN118439998A (zh) 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
JP2003335670A (ja) 癒着防止剤
HK1169650B (en) Novel phenol derivative

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120328

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160415

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160701

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160803

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160803

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200429

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210520

Start annual number: 6

End annual number: 6